Genetically Programmable Vesicles for Enhancing CAR‐T Therapy Against Solid Tumors

Xianjun Li,Tianchuan Zhu,Ronghao Wang,Jian Chen,Lantian Tang,Wenwen Huo,Xi Huang,Qingdong Cao

DOI: https://doi.org/10.1002/adma.202211138

IF: 29.4

2023-02-24

Advanced Materials

Abstract:CAR‐T cell therapy has shown remarkable success in eradicating hematologic malignancies. However, its efficacy in treating solid tumors has always been limited due to the presence of an immune‐suppressive tumor microenvironment. Here, genetically programmable cellular vesicles expressing high‐affinity anti‐PD‐L1 scFv loaded with glutamine antagonist (D@aPD‐L1 NVs) are developed to metabolically dismantle the immunosuppressive tumor microenvironment and enhance the efficiency of anti‐mesothelin CAR‐T cells in orthotopic lung cancer. As anti‐PD‐L1 scFv can specifically bind to the PD‐L1 on tumor cells, D@aPD‐L1 NVs enable the targeted delivery of glutamine antagonists to the tumor site, disturb PD‐1/PD‐L1 inhibitory signaling, and address the upregulation of PD‐L1 on tumor cells caused by the treatment of glutamine antagonists and CAR‐T cells, which prevents the premature exhaustion of CAR‐T cells. More importantly, D@aPD‐L1 NVs effectively reduce the number of immunosuppressive cells and promote the recruitment of inflammatory cells and the secretion of inflammatory cytokines in tumor tissues. These unique features of D@aPD‐L1 NVs improve the infiltration and effector functions of CAR‐T cells, which ultimately enhance the anti‐tumor ability and long‐term memory immunity of CAR‐T cells. Our findings support that D@aPD‐L1 NVs act as a promising drug to strengthen the effectiveness of CAR‐T cells against solid tumors. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology